Gregg Fergus

Were not your typical research company. At UserCue, we believe in breaking the barriers of conventional research methods. By creating bespoke AI research agents for each project, we fully automate end-to-end research processes. In minutes, not months, we deliver nuanced insights, turning lengthy and costly research studies into agile, actionable intelligence. By sending out a simple link, our agent can perform up to 1,000 in-depth interviews per hour. UserCues adaptability extends across market research, strategic consulting, political polling, and in-house insights. Our clients use UserCue for a wide range of purposes, including primary research interviews, message testing, voter sentiment, market landscaping and more. By providing nuanced insights into large populations or targeted groups, UserCue enables organizations to make informed decisions quickly, confidently, and within budget. Book a demo today to learn more about UserCue and how we can streamline research projects and provide AI system solutions for your business.

Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.

AIQ Solutions is a group of passionate entrepreneurs, scientists, and engineers with a vision to improve treatment outcomes for patients with a wide range of complex diseases, all around the world. Leveraging a strong foundation of intellectual property, AIQ is continuously innovating. By combining ingenuity with rigorous clinical validation, AIQ is changing how clinicians manage complex diseases.

Celsee, Inc., is harnessing the gentle power of gravity to break down barriers in single-cell analysis. Our technology’s unparalleled capture and viability rates, plus the ability to scale easily to millions of cells, deliver high-confidence results for applications such as single-cell cytometry, proteogenomics, transcriptomics, and rare-cell enumeration. With Celsee’s Genesis system, users can achieve accurate biological insight by capturing more cells, because every cell matters. Celsee is a privately held company based in Ann Arbor, Michigan.

Cernostics has joined Castle Biosciences. Please stay connected! https://www.linkedin.com/company/castle-biosciences-inc-/ Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.

Verda Bio seeks to bring scientific expertise to product formulation and dosing of cannabinoid based therapeutics (CBTs). At Verda Bio, we are performing research on CBTs using the latest scientific technology to perform genomic, analytical, and clinical research on CBTs. At Verda Bio, genomic and analytical data will serve as the backbone for CBT development. By combining analytical chemistry, technology, and genomic data, Verda Bio will be able to control for the variability in many cannabis strains and create CBTs (cannabinoid based therapeutics) that selectively and consistently meet the needs of specific patient populations.

The All-Access Pass to Owning Your Fandom #FLOW #NFT

At Quantum-Si we have a created a very unique environment where bright, highly committed individuals are given the freedom, ownership, and resources to solve tough problems and be the first to do new science. We are fully-funded by successful founders so employees can focus on creating, building, learning, and getting to market products that will change the world. If you are looking for a new challenge, check out our job postings at https://www.4catalyzer.com Empower discovery. Empower health. Empower you.

Butterfly’s mission is to create access to valuable clinical insights using innovative ultrasound technology, made simple with artificial intelligence, to benefit all patients worldwide. Through the delivery of high-quality, affordable, easy-to-use, intelligently connected ultrasound, Butterfly Network enables better clinical decisions through better information and insight at the point of care. With Butterfly, seeing is knowing – in the hospital, community, or home. iQ3: Best Medical Technology Winner @ 2024 Prix Galien USA Awards

Hyperfine’s mission is to make MRI accessible to every patient, regardless of income or resources. Anytime. Anywhere. Hyperfine’s Swoop® Portable MR Imaging System™ addresses limitations of current imaging technologies. Swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an Apple iPad® for control. Images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. Designed as a complementary system to fixed conventional MRI systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. The complete Swoop™ Portable MR Imaging System costs less than the annual service contract for most fixed conventional MRI systems. In August 2020, Swoop received market-ready FDA clearance for portable MR imaging of the brain and head for patients of all ages and additional clearance for its Advanced AI Applications image analysis software in January 2021. Leading organizations have recognized Swoop as one of the most innovative health care technologies available today. -Fast Company Magazine recognized Swoop as a 2021 World Changing Idea -Fierce Medtech recognized Hyperfine as a 2020 Fierce 15 company for its innovative and creative approach to developing solutions for healthcare providers and patients -Swoop won the American College of Emergency Physicians (ACEP) 2020 incubatED Medical Device Innovation Challenge as a solution that will shape the future of emergency medicine -Hyperfine received the Best Practices Product Innovation Award from Frost & Sullivan. They described the disruptive technology as a “massive leap forward to democratizing MRI” -Aunt Minnie named Hyperfine as a finalist for Best New Radiology Vendor in its 2020 Minnies Awards. -Swoop was also recognized as a CES 2021 Innovation Awards Honoree

At OrphAI Therapeutics, we are focused on identifying and developing therapeutics for rare orphan conditions. We accelerate the development process by using a variety of methods to identify and acquire promising pipeline assets - including data mining, deep learning, and in-licensing. Our current clinical stage drug candidates target several orphan disorders including pulmonary sarcoidosis, bronchiolitis obliterans post lung transplant and amyotrophic lateral sclerosis.

Igenomix is a medical testing laboratory specializing in reproductive genetic services. We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive. In 2021, Vitrolife acquired Igenomix, a leader in reproductive genetic testing services for IVF clinics, founded in 2011. Together we create Vitolife Group, a global leader in reproductive health. By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Based on science and advanced research capabilities, our aim is to deliver products and services for the entire fertility journey, providing consistent performance and guaranteed quality. We are a sustainable market leader and aim to be the preferred partner to the fertility clinics by providing superior products and services. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our products and services are available in more than 110 countries, through our own presence in 30 countries, and a network of distributors. Our vision is to fulfil the dream of having a healthy baby, and we achieve this by supporting our customers in delivering successful treatment outcomes. We are your committed partner for the IVF journey. We can help you maximise success. – Together. All the way. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.

Were not your typical research company. At UserCue, we believe in breaking the barriers of conventional research methods. By creating bespoke AI research agents for each project, we fully automate end-to-end research processes. In minutes, not months, we deliver nuanced insights, turning lengthy and costly research studies into agile, actionable intelligence. By sending out a simple link, our agent can perform up to 1,000 in-depth interviews per hour. UserCues adaptability extends across market research, strategic consulting, political polling, and in-house insights. Our clients use UserCue for a wide range of purposes, including primary research interviews, message testing, voter sentiment, market landscaping and more. By providing nuanced insights into large populations or targeted groups, UserCue enables organizations to make informed decisions quickly, confidently, and within budget. Book a demo today to learn more about UserCue and how we can streamline research projects and provide AI system solutions for your business.

Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.

AIQ Solutions is a group of passionate entrepreneurs, scientists, and engineers with a vision to improve treatment outcomes for patients with a wide range of complex diseases, all around the world. Leveraging a strong foundation of intellectual property, AIQ is continuously innovating. By combining ingenuity with rigorous clinical validation, AIQ is changing how clinicians manage complex diseases.

Celsee, Inc., is harnessing the gentle power of gravity to break down barriers in single-cell analysis. Our technology’s unparalleled capture and viability rates, plus the ability to scale easily to millions of cells, deliver high-confidence results for applications such as single-cell cytometry, proteogenomics, transcriptomics, and rare-cell enumeration. With Celsee’s Genesis system, users can achieve accurate biological insight by capturing more cells, because every cell matters. Celsee is a privately held company based in Ann Arbor, Michigan.

Cernostics has joined Castle Biosciences. Please stay connected! https://www.linkedin.com/company/castle-biosciences-inc-/ Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.